Accredo, Inc., Pine Brook, NJ. RATIONALE: Intravenous immunoglobulin (IVIG) infusions are associated with predictable adverse drug reactions (ADRs), some of which are life threatening. The application of a clinical program at the specialty pharmacy (SP) level can decrease both the frequency and severity of reactions. METHODS: A retrospective review of 4,155 patients receiving IVIG over a 10-month period was conducted using the specialty pharmacy electronic medical record. Patients were included if they placed at least one refill of IVIG, age fell between 18 and 89 years, and a refill assessment template was completed and reviewed by a pharmacist for every refill placed. Data included diagnosis, brand, dose and frequency of the IVIG, and history of patient reported problems since the previous infusion. For problems determined to be ADRs, nursing notes were reviewed for premedication regimens, concentration and rate of infusion of the IVIG, and patient tolerability. RESULTS: 6.4% (4,588/32,537) of assessments revealed a patient reported problem since the previous infusion of IVIG. The majority of these problems were infections (2,897/4,588) or involved the mechanics during administration (1,318/4,588) . The number of true ADRs was 373, revealing an adverse event rate associated with the infusion of IVIG in the home of 0.53% (373/32,537). Two of these reactions were considered life threatening (anaphylaxis and pulmonary embolism), while sixteen were classified as severe (potential aseptic meningitis or thromboembolic event). CONCLUSIONS: Our data show that the application of an evidencebased clinical care management program can reduce the incidence of ADRs associated with IVIG below the literature benchmark. RATIONALE: ABPA is associated with deteriorating lung function and is a common complication in asthma patients. Long-term therapy with oral corticosteroids is usually required for repeated exacerbations, resulting in drug toxicity. It has been reported that anti-IgE therapy with omalizumab can be an effective therapy option in ABPA patients. METHODS: We report 3 asthma patients with ABPA taking prednisone at 20mg/day for patient 1 (M, 45y.o.), 40mg/day for patient 2 (M, 70y.o.), and 20mg/day for patient 3 (F, 31y.o.); also treated with omalizumab 375 mg every 2, 3, and 4 weeks for patient 1, 2, and 3 respectively. Patients were evaluated for steroid reduction, respiratory symptoms, and pulmonary function parameters. RESULTS: All 3 patients had skin test positivity to A. fumigatus, bronchiectasis, and high IgE levels suggesting ABPA diagnosis. For Patient 1, prednisone was decreased to 10mg/day 3 months after starting omalizumab treatment (OT) and stopped 9 months after. Patient 2 and 3 stopped taking prednisone 12 and 3 months after OT, respectively. All patients reported about 3 ABPA exacerbation per year prior to OT and about 1 exacerbation while on omalizumab. Only patient 1 experienced FEV1 improvement from baseline (2.70l to 3.00l) 3 months after OT. Patients reported significant clinical improvement of respiratory symptoms, decreased exacerbations, and overall improvement in health as early as 3 months after therapy. CONCLUSIONS: Omalizumab has the potential to be an effective alternative or as an additional therapy option for ABPA in asthma patients who fail to respond to corticosteroids, providing a steroid sparring effect.
